Biocon - Commercialization Issues Impact Q3 Earnings: Motilal Oswal 
A technician works at Biocon facility in Bengaluru. (Photographer: Namas Bhojani/ Bloomberg)

Biocon - Commercialization Issues Impact Q3 Earnings: Motilal Oswal 

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Dr. Christiane Hamacher has stepped down as Managing Director as well as from the board of Biocon Biologics Ltd. effective Jan. 20, 2021, due to professional differences with the chairperson on strategic priorities and the vision for BB.

Dr. Kiran will assume the position of Executive Chairperson at BB. Dr. Arun Chandavarkar will be the new MD and CEO for the next two years.

Biocon Ltd. delivered lower-than-expected Q3 FY21, largely weighed by:

  1. decline in generics sales, and

  2. slower ramp-up in Biosimilars off-take due to Covid-19.

It continues to build a product pipeline of biosimilars/generics.

Click on the attachment to read the full report:

Motilal Oswal Biocon Q3FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.